|
May 9
|
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 9
|
Kronos Bio Reports First-Quarter 2024 Financial Results
|
|
May 6
|
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
|
|
Apr 24
|
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Mar 27
|
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Mar 21
|
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
|
|
Mar 7
|
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
|
|
Mar 5
|
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
|
|
Jan 1
|
We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
|
|
Dec 18
|
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
|
|
Dec 4
|
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
|
|
Nov 27
|
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
|
|
Apr 24
|
Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors
|